These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

467 related items for PubMed ID: 9025710

  • 21. Elite volunteer athletes of different sport disciplines may have elevated baseline GH levels divorced from unaltered levels of both IGF-I and GH-dependent bone and collagen markers: a study on-the-field.
    Sartorio A, Marazzi N, Agosti F, Faglia G, Corradini C, De Palo E, Cella S, Rigamonti A, Muller EE.
    J Endocrinol Invest; 2004 May; 27(5):410-5. PubMed ID: 15279071
    [Abstract] [Full Text] [Related]

  • 22. Growth hormone (GH) effects on bone and collagen turnover in healthy adults and its potential as a marker of GH abuse in sports: a double blind, placebo-controlled study. The GH-2000 Study Group.
    Longobardi S, Keay N, Ehrnborg C, Cittadini A, Rosén T, Dall R, Boroujerdi MA, Bassett EE, Healy ML, Pentecost C, Wallace JD, Powrie J, Jørgensen JO, Saccà L.
    J Clin Endocrinol Metab; 2000 Apr; 85(4):1505-12. PubMed ID: 10770189
    [Abstract] [Full Text] [Related]

  • 23. Age related changes in biochemical markers of bone metabolism in horses.
    Price JS, Jackson B, Eastell R, Goodship AE, Blumsohn A, Wright I, Stoneham S, Lanyon LE, Russell RG.
    Equine Vet J; 1995 May; 27(3):201-7. PubMed ID: 7556047
    [Abstract] [Full Text] [Related]

  • 24. Abnormal bone turnover in monoclonal gammopathy of undetermined significance: analyses of type I collagen telopeptide, osteocalcin, bone-specific alkaline phosphatase and propeptides of type I and type III procollagens.
    Vejlgaard T, Abildgaard N, Jans H, Nielsen JL, Heickendorff L.
    Eur J Haematol; 1997 Feb; 58(2):104-8. PubMed ID: 9111591
    [Abstract] [Full Text] [Related]

  • 25. Effect of growth hormone (GH) replacement on plasma carboxy-terminal propeptide of type I procollagen (PICP) and pyridinoline cross-linked carboxyterminal telopeptide of type I collagen (ICTP) levels in GH-deficient adult patients.
    Murakami Y, Sugitani M, Koshimura K, Sohmiya M, Kato Y.
    Endocr J; 1998 Apr; 45 Suppl():S121-4. PubMed ID: 9790245
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Evaluation of the optimum dose of growth hormone (GH) for restoring bone mass in adult-onset GH deficiency: results from two 12-month randomized studies.
    Abrahamsen B, Hangaard J, Horn HC, Hansen TB, Gregersen G, Hansen-Nord M, Vahl N, Junker P, Andersen M, Hagen C.
    Clin Endocrinol (Oxf); 2002 Aug; 57(2):273-81. PubMed ID: 12153608
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Effects of 42 months of GH treatment on bone mineral density and bone turnover in GH-deficient adults.
    Välimäki MJ, Salmela PI, Salmi J, Viikari J, Kataja M, Turunen H, Soppi E.
    Eur J Endocrinol; 1999 Jun; 140(6):545-54. PubMed ID: 10377504
    [Abstract] [Full Text] [Related]

  • 30. The effects of prolonged growth hormone replacement on bone metabolism and bone mineral density in hypopituitary adults.
    Beshyah SA, Kyd P, Thomas E, Fairney A, Johnston DG.
    Clin Endocrinol (Oxf); 1995 Mar; 42(3):249-54. PubMed ID: 7758229
    [Abstract] [Full Text] [Related]

  • 31. Effects of two years of growth hormone (GH) replacement therapy on bone metabolism and mineral density in childhood and adulthood onset GH deficient patients.
    Longobardi S, Di Rella F, Pivonello R, Di Somma C, Klain M, Maurelli L, Scarpa R, Colao A, Merola B, Lombardi G.
    J Endocrinol Invest; 1999 May; 22(5):333-9. PubMed ID: 10401706
    [Abstract] [Full Text] [Related]

  • 32. Effect of long-term treatment with GH on bone metabolism, bone mineral density and bone elasticity in GH-deficient adults.
    Kann P, Piepkorn B, Schehler B, Andreas J, Lotz J, Prellwitz W, Beyer J.
    Clin Endocrinol (Oxf); 1998 May; 48(5):561-8. PubMed ID: 9666867
    [Abstract] [Full Text] [Related]

  • 33. Characteristics of biochemical markers in patients with metabolic bone disorders.
    Hoshino H, Kushida K, Takahashi M, Kawana K, Denda M, Yamazaki K, Inoue T.
    Endocr Res; 1998 Feb; 24(1):55-64. PubMed ID: 9553754
    [Abstract] [Full Text] [Related]

  • 34. Growth hormone replacement therapy improves body composition and increases bone metabolism in elderly patients with pituitary disease.
    Fernholm R, Bramnert M, Hägg E, Hilding A, Baylink DJ, Mohan S, Thorén M.
    J Clin Endocrinol Metab; 2000 Nov; 85(11):4104-12. PubMed ID: 11095440
    [Abstract] [Full Text] [Related]

  • 35. Normal osteoclastic and osteoblastic responses to exogenous growth hormone in patients with postmenopausal spinal osteoporosis.
    Kassem M, Brixen K, Blum WF, Mosekilde L, Eriksen EF.
    J Bone Miner Res; 1994 Sep; 9(9):1365-70. PubMed ID: 7817819
    [Abstract] [Full Text] [Related]

  • 36. Collagen formation and degradation increase during growth hormone therapy in children.
    Vihervuori E, Turpeinen M, Siimes MA, Koistinen H, Sorva R.
    Bone; 1997 Feb; 20(2):133-8. PubMed ID: 9028537
    [Abstract] [Full Text] [Related]

  • 37. Effects of 12 months rec-GH therapy on bone and collagen turnover and bone mineral density in GH deficient children with thalassaemia major.
    Sartorio A, Conte G, Conti A, Masala A, Alagna S, Rovasio P, Faglia G.
    J Endocrinol Invest; 2000 Jun; 23(6):356-61. PubMed ID: 10908162
    [Abstract] [Full Text] [Related]

  • 38. Long-term monitoring of rec-GH treatment by serial determination of serum aminoterminal propeptide of type III procollagen in children and adults with GH deficiency.
    Sartorio A, Arosio M, Conti A, Ferrero S, Porretti S, Faglia G.
    J Endocrinol Invest; 1999 Mar; 22(3):169-75. PubMed ID: 10219883
    [Abstract] [Full Text] [Related]

  • 39. Effects of a growth hormone receptor antagonist on bone markers in acromegaly.
    Fairfield WP, Sesmilo G, Katznelson L, Pulaski K, Freda PU, Stavrou S, Kleinberg D, Klibanski A.
    Clin Endocrinol (Oxf); 2002 Sep; 57(3):385-90. PubMed ID: 12201832
    [Abstract] [Full Text] [Related]

  • 40. Additional beneficial effects of alendronate in growth hormone (GH)-deficient adults with osteoporosis receiving long-term recombinant human GH replacement therapy: a randomized controlled trial.
    Biermasz NR, Hamdy NA, Janssen YJ, Roelfsema F.
    J Clin Endocrinol Metab; 2001 Jul; 86(7):3079-85. PubMed ID: 11443170
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 24.